Summary
Rosetta Genomics Ltd (RGL) is a developer of next generation diagnostic tests for personalized medicine. The company provides testing services such as cancer origin, next-gen, thyroid, lung, prostate, bladder, breast, kidney and specialty tests. It also develops tests for thyroid neoplasia, oncology, kidney rejection, Alzheimer's disease, therapeutics and CMV. The company offers RosettaGX platform on the cutting edge of molecular science and genomic testing technologies, with tests. It operates in Australia, New Zealand, Israel, Singapore, Canada, Greece, India, Saudi Arabia, Qatar, the UAE, Israel and Turkey. RGL is headquartered in Rehovot, Israel.
Rosetta Genomics Ltd (ROSG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Rosetta Genomics Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Rosetta Genomics Enters into Research Agreement with Sheba Medical Center 11
Rosetta Genomics Enters into Co-Development Agreement with Institute of Molecular Translational Medicine 12
Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 13
Rosetta Genomics Enters into Co-Development Agreement with Weizmann Institute of Science 14
Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 15
Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer 17
Rosetta Genomics Enters Into Collaboration With UC Davis 18
Licensing Agreements 19
Mirna Therapeutics Enters into Sublicensing Agreement with Rosetta Genomics 19
Equity Offering 20
Rosetta Genomics to Raise up to USD7.5 Million in Public Offering of Units 20
Rosetta Genomics Raises USD5 Million in Second and Final Tranche of Private Placement of Shares 21
Rosetta Genomics Raises USD5 Million in First Tranche of Private Placement of Shares 22
Debt Offering 23
Rosetta Genomics Raises USD1.3 Million in Second Tranche of Private Placement of Debentures and Warrants 23
Rosetta Genomics Ltd - Key Competitors 24
Rosetta Genomics Ltd - Key Employees 25
Rosetta Genomics Ltd - Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Strategy And Business Planning 27
Jul 06, 2017: Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China 27
Financial Announcements 28
Mar 30, 2017: Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results 28
Sep 26, 2016: Rosetta Genomics Reports 2016 Second Quarter Financial Results 31
May 19, 2016: Rosetta Genomics Reports 2016 First Quarter Financial Results 33
Mar 23, 2016: Rosetta Genomics Reports 2015 Full Year Financial Results 35
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37
List of Tables
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Rosetta Genomics Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Rosetta Genomics Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Rosetta Genomics Enters into Research Agreement with Sheba Medical Center 11
Rosetta Genomics Enters into Co-Development Agreement with Institute of Molecular Translational Medicine 12
Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 13
Rosetta Genomics Enters into Co-Development Agreement with Weizmann Institute of Science 14
Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 15
Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer 17
Rosetta Genomics Enters Into Collaboration With UC Davis 18
Mirna Therapeutics Enters into Sublicensing Agreement with Rosetta Genomics 19
Rosetta Genomics to Raise up to USD7.5 Million in Public Offering of Units 20
Rosetta Genomics Raises USD5 Million in Second and Final Tranche of Private Placement of Shares 21
Rosetta Genomics Raises USD5 Million in First Tranche of Private Placement of Shares 22
Rosetta Genomics Raises USD1.3 Million in Second Tranche of Private Placement of Debentures and Warrants 23
Rosetta Genomics Ltd, Key Competitors 24
Rosetta Genomics Ltd, Key Employees 25
Rosetta Genomics Ltd, Other Locations 26
Rosetta Genomics Ltd, Subsidiaries 26
List of Figures
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Rosetta Genomics Ltd, Medical Devices Deals, 2011 to YTD 2017 9
